Large Eczema Area and Severity Index response at 2-year follow-up of patients treated with dupilumab in routine care of atopic dermatitis: results from the national registry TREATgermany

Luise Heinrich; Thomas Birkner; Susanne Abraham; Sascha Gerdes; T. Honstein; Sigrid Müller; Matthias Augustin; Inken Harder; Thomas Schaefer; Andreas Pinter; Anne B. Bong; Jutta Ramaker‐Brunke; Tilo Biedermann; Michael Sticherling; Hannah Gorriahn‐Maiterth; Knut Schäkel; Beate Schwarz; Sven Quist; Mohammad Asefi; Nancy E. Adler; Maren Stahl; M. Schulz-Kiesow; Florian Schenck; Thomas Werfel; Stephan Weidinger; Annice Heratizadeh; Jochen Schmitt

doi:10.1093/skinhd/vzaf075

Key Points

EASI 75 response was achieved in 78.8% of patients treated with dupilumab by month 24.
The cohort of 294 patients represents one of the largest analyses of long-term dupilumab treatment in atopic dermatitis.
Registry data from TREATgermany highlights the successful use of dupilumab therapy in routine clinical settings.
The study adheres to the HOME core outcome set, enhancing standardization for future evaluations.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Analysis finds significant EASI 75 and EASI 90 responses in atopic dermatitis patients treated with dupilumab, suggesting routine care effectiveness.

Abstract

The TREATgermany registry was set up in 2016. We provide results on long-term dupilumab therapy in adults with moderate and severe atopic dermatitis (AD) in a routine care setting. The analysis cohort of 294 patients is one of the largest cohorts with 2-year follow-up data on treatment effects of dupilumab obtained from an AD registry to date. We report the Harmonising Outcome Measures for Eczema (HOME) core outcome set. The Eczema Area Severity Index (EASI) 75 and EASI 90 response rates for patients on treatment at month 24 were 78.8% and 51.2%, respectively.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Heinrich et al. (2025) studied this question.

synapsesocial.com/papers/68de6f3183cbc991d0a2218c https://doi.org/10.1093/skinhd/vzaf075

View Full Paper

Ask AI

Bookmark

Share

Large Eczema Area and Severity Index response at 2-year follow-up of patients treated with dupilumab in routine care of atopic dermatitis: results from the national registry TREATgermany

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Large Eczema Area and Severity Index response at 2-year follow-up of patients treated with dupilumab in routine care of atopic dermatitis: results from the national registry TREATgermany

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading